The "knowns" and "unknowns" of biologic therapy in ankylosing spondylitis

Lianne Gensler, Robert Inman, Atulya (Atul) Deodhar

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Since the first biologic agent was tested in the treatment of ankylosing spondylitis (AS), the ability of these therapies to dramatically improve the clinical symptoms and signs of the disease was very evident. Over the past decade, 4 tumor necrosis factor-alpha inhibitors have been approved by the Food and Drug Administration for the treatment of AS. Published data include randomized controlled trials, registries and observational studies. Guidelines have also been developed for the use of biologics in AS. Although a lot is known about the use of biologics in the AS, several "unknowns" remain. Whether these agents can alter the natural history of AS if started very early in the course or whether they can prevent extra-articular manifestations are among the important unanswered questions. Most of the data summarized in this review relate to tumor necrosis factor-alpha inhibitors, and other biologic agents that have been studied are included, as well. This review also summarizes what questions remain about the use of biologics in AS and what type of studies will be required to answer them.

Original languageEnglish (US)
Pages (from-to)360-363
Number of pages4
JournalAmerican Journal of the Medical Sciences
Volume343
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Biological Therapy
Ankylosing Spondylitis
Biological Products
Biological Factors
Tumor Necrosis Factor-alpha
United States Food and Drug Administration
Signs and Symptoms
Observational Studies
Registries
Therapeutics
Randomized Controlled Trials
Joints
Guidelines

Keywords

  • Ankylosing spondylitis
  • Biologics
  • TNF-alpha inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The "knowns" and "unknowns" of biologic therapy in ankylosing spondylitis. / Gensler, Lianne; Inman, Robert; Deodhar, Atulya (Atul).

In: American Journal of the Medical Sciences, Vol. 343, No. 5, 05.2012, p. 360-363.

Research output: Contribution to journalArticle

@article{dbb8994e917e4a6c9b329a6406dee8d5,
title = "The {"}knowns{"} and {"}unknowns{"} of biologic therapy in ankylosing spondylitis",
abstract = "Since the first biologic agent was tested in the treatment of ankylosing spondylitis (AS), the ability of these therapies to dramatically improve the clinical symptoms and signs of the disease was very evident. Over the past decade, 4 tumor necrosis factor-alpha inhibitors have been approved by the Food and Drug Administration for the treatment of AS. Published data include randomized controlled trials, registries and observational studies. Guidelines have also been developed for the use of biologics in AS. Although a lot is known about the use of biologics in the AS, several {"}unknowns{"} remain. Whether these agents can alter the natural history of AS if started very early in the course or whether they can prevent extra-articular manifestations are among the important unanswered questions. Most of the data summarized in this review relate to tumor necrosis factor-alpha inhibitors, and other biologic agents that have been studied are included, as well. This review also summarizes what questions remain about the use of biologics in AS and what type of studies will be required to answer them.",
keywords = "Ankylosing spondylitis, Biologics, TNF-alpha inhibitors",
author = "Lianne Gensler and Robert Inman and Deodhar, {Atulya (Atul)}",
year = "2012",
month = "5",
doi = "10.1097/MAJ.0b013e318251406c",
language = "English (US)",
volume = "343",
pages = "360--363",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - The "knowns" and "unknowns" of biologic therapy in ankylosing spondylitis

AU - Gensler, Lianne

AU - Inman, Robert

AU - Deodhar, Atulya (Atul)

PY - 2012/5

Y1 - 2012/5

N2 - Since the first biologic agent was tested in the treatment of ankylosing spondylitis (AS), the ability of these therapies to dramatically improve the clinical symptoms and signs of the disease was very evident. Over the past decade, 4 tumor necrosis factor-alpha inhibitors have been approved by the Food and Drug Administration for the treatment of AS. Published data include randomized controlled trials, registries and observational studies. Guidelines have also been developed for the use of biologics in AS. Although a lot is known about the use of biologics in the AS, several "unknowns" remain. Whether these agents can alter the natural history of AS if started very early in the course or whether they can prevent extra-articular manifestations are among the important unanswered questions. Most of the data summarized in this review relate to tumor necrosis factor-alpha inhibitors, and other biologic agents that have been studied are included, as well. This review also summarizes what questions remain about the use of biologics in AS and what type of studies will be required to answer them.

AB - Since the first biologic agent was tested in the treatment of ankylosing spondylitis (AS), the ability of these therapies to dramatically improve the clinical symptoms and signs of the disease was very evident. Over the past decade, 4 tumor necrosis factor-alpha inhibitors have been approved by the Food and Drug Administration for the treatment of AS. Published data include randomized controlled trials, registries and observational studies. Guidelines have also been developed for the use of biologics in AS. Although a lot is known about the use of biologics in the AS, several "unknowns" remain. Whether these agents can alter the natural history of AS if started very early in the course or whether they can prevent extra-articular manifestations are among the important unanswered questions. Most of the data summarized in this review relate to tumor necrosis factor-alpha inhibitors, and other biologic agents that have been studied are included, as well. This review also summarizes what questions remain about the use of biologics in AS and what type of studies will be required to answer them.

KW - Ankylosing spondylitis

KW - Biologics

KW - TNF-alpha inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84860820862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860820862&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0b013e318251406c

DO - 10.1097/MAJ.0b013e318251406c

M3 - Article

VL - 343

SP - 360

EP - 363

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 5

ER -